XML 30 R19.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates under a single segment based on an analysis of the Company's reporting structure, the information available to the Chief Operating Decision Maker (“CODM”), and the strategic decisions being made by management. The Company provides services to a diverse client base, which includes community-based pathology and oncology practices, hospital pathology labs, reference labs, academic centers, and pharmaceutical companies. Revenue is derived from clients by providing clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions.
The Company's Chief Executive Officer serves as the CODM. The CODM uses net loss, as reported on the Consolidated Statements of Operations, to monitor budget versus actual results to evaluate profitability and allocate resources. The CODM is regularly provided with financial information, including revenue and expenses, in a format consistent with the Consolidated Statements of Operations. The CODM does not review assets at a different level or category than those disclosed in the Consolidated Balance Sheets. Substantially all of the Company's revenue and tangible long-lived assets are attributable to the U.S.
The following table summarizes segment information for the three months ended March 31, 2026, and 2025 (in thousands):
Three Months Ended March 31,
20262025
Net revenue$186,672 $168,035 
Less:
Amortization7,633 8,362 
Depreciation8,780 9,366 
Stock-based compensation9,636 10,754 
Other cost of revenue(1)
97,884 85,817 
Other general and administrative(1)
49,045 50,749 
Other research and development(1)
8,459 9,102 
Other sales and marketing(1)
23,476 21,710 
Loss from operations(18,241)(27,825)
Interest income(1,273)(3,721)
Interest expense598 1,618 
Other expense (income)12 (65)
Loss before taxes(17,578)(25,657)
Income tax expense (benefit)(472)266 
Net loss$(17,106)$(25,923)
_________________
(1) Excludes amounts related to amortization, depreciation, and stock-based compensation, as applicable.